pubmed.ncbi.nlm.nih.gov

Advances toward precision medicine for bipolar disorder: mechanisms & molecules - PubMed

Review

Advances toward precision medicine for bipolar disorder: mechanisms & molecules

Stephen J Haggarty et al. Mol Psychiatry. 2021 Jan.

Abstract

Given its chronicity, contribution to disability and morbidity, and prevalence of more than 2%, the effective treatment, and prevention of bipolar disorder represents an area of significant unmet medical need. While more than half a century has passed since the introduction of lithium into widespread use at the birth of modern psychopharmacology, that medication remains a mainstay for the acute treatment and prevention of recurrent mania/hypomania and depression that characterize bipolar disorder. However, the continued limited understanding of how lithium modulates affective behavior and lack of validated cellular and animal models have resulted in obstacles to discovering more effective mood stabilizers with fewer adverse side effects. In particular, while there has been progress in developing new pharmacotherapy for mania, developing effective treatments for acute bipolar depression remain inadequate. Recent large-scale human genetic studies have confirmed the complex, polygenic nature of the risk architecture of bipolar disorder, and its overlap with other major neuropsychiatric disorders. Such discoveries have begun to shed light on the pathophysiology of bipolar disorder. Coupled with broader advances in human neurobiology, neuropharmacology, noninvasive neuromodulation, and clinical trial design, we can envision novel therapeutic strategies informed by defined molecular mechanisms and neural circuits and targeted to the root cause of the pathophysiology. Here, we review recent advances toward the goal of better treatments for bipolar disorder, and we outline major challenges for the field of translational neuroscience that necessitate continued focus on fundamental research and discovery.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cade JF: Lithium salts in the treatment of psychotic excitement. vol. 2, pp. 349–52. Med J Aust (1949) - PubMed
    1. https://enacademic.com/dic.nsf/enwiki/9778 Accessed 1 July 2020.
    1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M et al.: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. vol. 64, pp. 543–52. Arch Gen Psychiatry (2007) - PMC - PubMed
    1. Schioldann J. History of the introduction of lithium into medicine and psychiatry: birth of modern psychopharmacology (1949). Adelaide. Academic Press
    1. Parker G, McCraw S, Hadzi-Pavlovic D, Fletcher K: Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. vol. 149, pp. 46–55. J Affect Disord (2013) - PubMed

Publication types

MeSH terms

Substances